View:
Download DOC
Download PDF
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 		 
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Fowler Wyche
(Last) (First) (Middle)
701 A STREET NE
(Street)
WASHINGTON DC 20002
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ZIOPHARM ONCOLOGY INC [ ZIOP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/10/2011
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $.001 par value 08/10/2011 P 5,000 A $5.1851(1) 72,500(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Director Stock Option (right to buy) $4.31 12/22/2006 12/22/2014 Common Stock, $.001 par value 15,029 15,029 D
Director Stock Option (riht to buy) $5.01 04/26/2006 04/26/2016 Common Stock 15,000 15,000 D
Director Stock Option (right to buy) $6.49 12/13/2006 12/13/2016 Common Stock 15,000 15,000 D
Stock Option (right to buy) $4.85 06/18/2010 06/18/2017 Common Stock 15,000 15,000 D
Stock Option (right to buy) $2.73 (3) 12/12/2017 Common Stock 20,000 20,000 D
Stock Option (right to buy) $0.7 (4) 05/13/2019 Common Stock 15,000 15,000 D
Stock Option (right to buy) $2.85 (5) 12/31/2019 Common Stock, $.001 par value 7,500 7,500 D
Stock Option (right to buy) $5.09 03/31/2011 03/31/2020 Common Stock, $.001 par value 15,000 15,000 D
Stock Option (right to buy) $4.77 (6) 12/31/2020 Common Stock 30,000 30,000 D
Explanation of Responses:
1. The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.15 to $5.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
2. Includes grants of restricted stock with restrictions that lapsed as to 3,750 shares on December 31, 2010 and 15,000 shares on March 31, 2011 and restrictions that will lapse as to 3,750 shares on December 31, 2011.
3. 6,667 shares vest on each of 12/12/08 and 12/12/09; 6,666 shares vest on 12/12/10.
4. 5,000 shares vest on each of 12/31/09, 6/30/2010 and 12/31/2010.
5. 3,750 shares vest on each of 12/31/2010 and 12/31/2011.
6. 10,000 shares vest on each of 12/31/2011, 12/31/2012 and 12/31/2013.
Remarks:
Exhibit 24.1 Power of Attorney
/s/ Richard E. Bagley, as attorney-in-fact for Wyche Fowler 08/11/2011
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
	POWER OF ATTORNEY

	For Executing Forms 3, 4 and 5

           Know all by these presents, that the undersigned hereby
constitutes and appoints Jonathan Lewis and Richard E. Bagley,
signing individually, his true and lawful attorneys-in-fact to:

1.	Execute for and on behalf of the undersigned Initial
Statements of Beneficial Ownership of Securities on
Form 3, Statements of Changes of Beneficial Ownership
of Securities on Form 4 and Annual Statements of
Beneficial Ownership of Securities on Form 5, for the
purpose of reporting transactions by the undersigned in
securities issued by Ziopharm Oncology, Inc. in
accordance with Section 16(a) of the Securities
Exchange Act of 1934 and the rules thereunder;

2.	Do and perform any and all acts for and on behalf of
the undersigned which may be necessary or desirable to
complete the execution of any such Form 3, 4 or 5 and
the timely filing thereof with the United States
Securities and Exchange Commission and any other
applicable governmental or regulatory authority; and

3.	Take any other action of any type whatsoever in
connection with the foregoing which in the opinion of
such attorney-in-fact, may be of benefit to, in the
best interest of, or legally required by, the
undersigned, it being understood that the documents
executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be
in such form and shall contain such terms and
conditions as such attorney-in-fact may approve in his
discretion.

           The undersigned hereby grants to each such attorney-in-fact
full power and authority to do and perform all and every act and
thing whatsoever requisite, necessary and proper to be done in the
exercise of any of the rights and powers herein granted, as fully
to all intents and purposes as such attorney-in-fact might or could
do if personally present, with full power of substitution or
revocation, hereby ratifying and confirming all that such attorney-
in-fact, or his substitute or substitutes, shall lawfully do or
cause to be done by virtue of this power of attorney and the rights
and powers herein granted.  The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the
request of the undersigned, are not assuming any of the
undersigned's responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934.

           This Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file Forms 3, 4 and
5 with respect to the undersigned's holdings of and transactions in
securities issued by Ziopharm Oncology, Inc., unless earlier
revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

           IN WITNESS WHEREOF, the undersigned has executed this Power
of Attorney as of this  24th  day of June, 2009.

			/s/ Wyche Fowler, Jr.

			(signature)

			Wyche Fowler, Jr.